Mortality, Severity, and Hospital Admission among COVID-19 Patients with ACEI/ARB Use: A Meta-Analysis Stratifying Countries Based on Response to the First Wave of the Pandemic.

ABSTRACT:

Background

The use of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) is controversial for treating COVID-19 patients. We aimed to estimate pooled risks of mortality, disease severity, and hospitalization associated with ACEI/ARB use and stratify them by country and country clusters.

Methods

We conducted a search in various databases through 4 July 2020 and then applied random-effects models to estimate pooled risks (OR_p) across stratifications by country cluster. Clusters were chosen to reflect outbreak times (China followed by Korea/Italy, others subsequently) and mobility restrictions (China and Denmark/France/Spain with stricter lockdowns than the UK/US).

Results

Overall analysis showed no increase in mortality;

SUBMITTER: Alamer AA 

PROVIDER: S-EPMC7912160 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature